Pulmonary drug delivery devices assist in efficient treatment of various respiratory conditions. The respiratory indications such as shortness of breathing, blocking of airways, lungs, formation of mucus, cough etc. Growth in the incidence rate of pulmonary disorders across the globe is expected to surge the number of patients who will require diagnosis and treatment for several respiratory conditions.
The global Pulmonary Drug Delivery Devices Market was valued at US$ 32,277.7 Mn in 2015 and is expected to propagate at a CAGR of 3.3% during the forecast period from 2016 to 2024 to reach US$ 43,053.3 Mn in 2024.
Asthma is a disease with many variations, usually with characterized by chronic airways inflammation. While COPD is the condition that restrict the airflow in the lungs and form disabling conditions as it is a chronic disease. The Pulmonary arterial hypertension (PAH) and cystic fibrosis (CF) are the rare diseases, where the PAH is characterized by the high blood pressure in the pulmonary artery which leads to progressive disorder and CF is an life threatening genetic disorder. Allergic rhinitis which is caused by the allergens (pollens) affects around 10-30 percent of the population globally and is the third common chronic disease in children under 18 years old.
Based on product type, the pulmonary drug delivery devices market has been categorized into Dry Powder Inhalers, Metered Dose Inhalers and Nebulizers, these three product types are further segmented on the basis of device mechanism. The dry powder inhalers are divided into single dose inhalers and multi dose inhalers. Metered dose inhalers segment is divided in to manually-actuated pressurized inhaler and breath-actuated pressurized inhaler. Whereas nebulizers are sub-segmented into three type jet nebulizers, ultrasonic wave nebulizers and vibrating mesh nebulizers. The global pulmonary drug delivery devices market was valued at US$ 32,277.7 million in 2015 and is anticipated to drain at a CAGR of 3.3 % from 2015 to 2024 and will reach at US$ 43,053.3 million in 2024.
Download PDF Brochure of Report – http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=873
By application the pulmonary drug delivery devices are classified into asthma, COPD, cystic fibrosis, and others. The others segment in applications comprises of Idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), allergic rhinitis, etc. On the basis of distribution channels, the pulmonary drug delivery devices market is segmented into retail pharmacies, hospital pharmacies, and E-commerce. The major geographies analyzed in the report include North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. In addition the regions have been further segmented by major countries from each region. The report also provides country level market estimation for the U.S., Canada, U.K., Germany, France, Brazil, Mexico, China, Japan, India, and Australia.
On the basis of geography the market for pulmonary drug delivery devices is dominated by North America in 2015 and is expected to contribute significantly during the forecast period from 2016 to 2024. In U.S. tobacco smoke is a key factor in development and progression of COPD. In 2014 COPD was the third leading cause of death in U.S. followed by Europe, which hold the second largest share of the pulmonary drug delivery devices market in terms of revenue. The cystic fibrosis is the common life threatening disease in Caucasian population and is incurable. Europe accounts around 32.5% of market share by the end of the forecasted period. Because of the increasing prevalence of pulmonary (respiratory) diseases in the low and middle- income countries the Asia-Pacific and Latin America are expected to serve great opportunity for the generic pulmonary drug and delivery devices during the forecasted period. Increasing population, demand for low cost drugs and rising awareness levels regarding the respiratory diseases are likely to drive the pulmonary drug delivery devices market in Asia-Pacific, Latin America and MEA
In North America U.S. attracts 93% of market share while Canada contribute for a very minor part.
Europe’s pulmonary drug delivery devices market is dominated by rest of the Europe and Germany in the forecasted period. In Asia Pacific the pulmonary drug delivery devices market is anticipated to be dominated by China at the end of the forecasted period.
Major players operating in the global pulmonary drug delivery devices market are AstraZeneca plc, Novartis AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, 3M Healthcare, Omron Corporation, and others. These players exhibit the largest geographical outreach with their presence in a wide range of pulmonary drug delivery devices world over.
The global pulmonary drug delivery devices market is segmented as follows:
Global Pulmonary Drug Delivery Devices Market Revenue, by Product type
- Dry Powder Inhalers
- Single-dose inhalers
- Multi-dose inhalers
- Metered Dose Inhalers
- Manually-actuated pressurized inhaler
- Breath-actuated pressurized inhaler
- Jet nebulizers
- Ultrasonic wave nebulizers
- Vibrating mesh nebulizers
Global Pulmonary Drug Delivery Devices Market Revenue, by Application
- Cystic Fibrosis
Global Pulmonary Drug Delivery Devices Market Revenue, by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
Global Pulmonary Drug Delivery Devices Market Revenue, by Geography
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Mr. Nachiket Ghumare
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453